Myriad Genetics (MYGN) Gains from Investment Securities (2016 - 2018)

Myriad Genetics (MYGN) has reported Gains from Investment Securities for 6 consecutive years, with $400000.0 the latest figure, recorded in Q3 2021.

• In Q3 2021, Gains from Investment Securities rose 108.89% year-over-year to $400000.0; the TTM figure through Sep 2021 stood at -$2.8 million (up 54.1% YoY), while the FY2020 annual figure was $2.8 million, up 300.0% from the prior year.
• Gains from Investment Securities held at $400000.0 in Q3 2021 per MYGN's latest filing, from $400000.0 in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $13.0 million in Q4 2017 and bottomed at -$73.2 million in Q3 2017.
• Historically, Gains from Investment Securities has averaged -$4.0 million across 5 years, with a median of $0.0 in 2018.
• Annual changes were most pronounced in 2017 — Gains from Investment Securities sank 14740.0% — and 2019, when it surged 620.0%.
• Myriad Genetics' Gains from Investment Securities stood at $13.0 million in 2017, then slumped by 107.69% to -$1.0 million in 2018, then soared by 620.0% to $5.2 million in 2019, then tumbled by 186.54% to -$4.5 million in 2020, then jumped by 108.89% to $400000.0 in 2021.
• Business Quant data shows MYGN's Gains from Investment Securities at $400000.0 in Q3 2021, $400000.0 in Q2 2021, and $900000.0 in Q1 2021.